Symbicort® – COPD Research

In keeping with AstraZeneca’s commitment to providing healthcare professionals and patients with useful information to help them make the best decisions about treatment, clinical data for Symbicort® are available on AstraZenecaClinicalTrials.com. This website contains summaries of results from completed clinical studies funded by AstraZeneca regarding currently marketed therapies and for any treatments in development that have been discontinued.

The following three COPD studies represent key clinical data that support the Symbicort indication in COPD.

• The Calverley COPD study [Study code SD-039-0670] Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic pulmonary disease. Eur Respir J 2003; 22:912–919.
• The Szafranski COPD study [Study code SD-039-0629] Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81.
• The CLIMB study [ClinicalTrials.gov Identifier: NCT00496470] Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to Spiriva in patients with chronic obstructive disease. Am J Respir Crit Care Med 2009; 180:1–10.

A summary of each COPD trial is provided below. Before prescribing any AZ products, healthcare professionals should view their country specific information.